Page last updated: 2024-12-11

10-methyl-9,10-dihydroacridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

10-methyl-9,10-dihydroacridine (10-MeDHA) is a chemical compound that belongs to the acridine family. It is structurally related to the well-known anti-malarial drug chloroquine and has attracted attention for its potential therapeutic applications.

**Structural features:**

* **Acridine core:** It contains the characteristic three-ringed acridine core, which gives the molecule its planar, aromatic structure.
* **Methyl group:** A methyl group is attached to the 10th carbon atom of the acridine ring.
* **Dihydro:** The molecule has two hydrogen atoms added to the 9th and 10th carbon atoms, resulting in a partially reduced ring system.

**Importance in research:**

10-MeDHA has shown promising activity in several research areas:

* **Anti-malarial activity:** It exhibits anti-malarial properties, potentially acting by interfering with the parasite's ability to digest heme, a crucial process in its survival. This suggests it could be a potential alternative or supplementary treatment for malaria.
* **Anti-cancer activity:** Studies have demonstrated that 10-MeDHA can inhibit the growth of certain cancer cell lines, including leukemia and breast cancer. It may achieve this by inducing apoptosis (programmed cell death) in cancer cells.
* **Anti-bacterial activity:** 10-MeDHA has been shown to possess antibacterial activity against various bacteria, including Staphylococcus aureus and Escherichia coli. This indicates it could be a potential candidate for the development of new antibiotics.
* **Anti-inflammatory activity:** Research has suggested that 10-MeDHA may have anti-inflammatory effects, potentially by modulating the activity of certain immune cells.

**Current research:**

Ongoing research is focused on understanding the precise mechanisms of action of 10-MeDHA and exploring its potential therapeutic applications. Scientists are investigating its pharmacokinetic properties, potential side effects, and its effectiveness in preclinical models of various diseases.

**Overall, 10-methyl-9,10-dihydroacridine is a promising compound with potential therapeutic benefits in various disease areas. However, further research is needed to determine its safety and efficacy before it can be considered for clinical use.**

10-methyl-9,10-dihydroacridine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5324693
CHEMBL ID2062588
SCHEMBL ID975897
MeSH IDM0458433

Synonyms (7)

Synonym
10-methyl-9h-acridine
inchi=1/c14h13n/c1-15-13-8-4-2-6-11(13)10-12-7-3-5-9-14(12)15/h2-9h,10h2,1h
n-methylacridan
CHEMBL2062588
SCHEMBL975897
10-methyl-9,10-dihydroacridine
n-methyl-acridan
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID673777Cytotoxicity in UV-irradiated human U937 cells exposed to photosensitizer for 2 hrs before irradiation for 20 mins by WST-1 assay2012ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4
Type 1 Phototherapeutic Agents. 2. Cancer Cell Viability and ESR Studies of Tricyclic Diarylamines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (37.50)29.6817
2010's5 (62.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.47 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]